Lyra Therapeutics (LYRA) Competitors $0.18 +0.01 (+5.88%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LYRA vs. ICAD, NTRB, LUCD, BLAC, CLGN, COCH, MDAI, SURG, XAIR, and NXGLShould you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include iCAD (ICAD), Nutriband (NTRB), Lucid Diagnostics (LUCD), Bellevue Life Sciences Acquisition (BLAC), CollPlant Biotechnologies (CLGN), Envoy Medical (COCH), Spectral AI (MDAI), SurgePays (SURG), Beyond Air (XAIR), and NEXGEL (NXGL). These companies are all part of the "medical equipment" industry. Lyra Therapeutics vs. iCAD Nutriband Lucid Diagnostics Bellevue Life Sciences Acquisition CollPlant Biotechnologies Envoy Medical Spectral AI SurgePays Beyond Air NEXGEL Lyra Therapeutics (NASDAQ:LYRA) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking. Do analysts recommend LYRA or ICAD? Lyra Therapeutics currently has a consensus price target of $4.50, indicating a potential upside of 2,400.00%. Given Lyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than iCAD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00iCAD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, LYRA or ICAD? Lyra Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Do insiders & institutionals have more ownership in LYRA or ICAD? 95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 24.6% of iCAD shares are held by institutional investors. 4.7% of Lyra Therapeutics shares are held by insiders. Comparatively, 10.3% of iCAD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is LYRA or ICAD more profitable? iCAD has a net margin of -17.81% compared to Lyra Therapeutics' net margin of -6,635.76%. iCAD's return on equity of -15.65% beat Lyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lyra Therapeutics-6,635.76% -125.07% -59.74% iCAD -17.81%-15.65%-12.52% Does the media refer more to LYRA or ICAD? In the previous week, iCAD had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for iCAD and 0 mentions for Lyra Therapeutics. iCAD's average media sentiment score of 0.75 beat Lyra Therapeutics' score of 0.00 indicating that iCAD is being referred to more favorably in the news media. Company Overall Sentiment Lyra Therapeutics Neutral iCAD Positive Which has preferable earnings & valuation, LYRA or ICAD? iCAD has higher revenue and earnings than Lyra Therapeutics. iCAD is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyra Therapeutics$1.47M8.01-$62.68M-$1.49-0.12iCAD$18.94M2.56-$4.85M-$0.13-14.08 Does the MarketBeat Community believe in LYRA or ICAD? iCAD received 204 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 62.13% of users gave iCAD an outperform vote while only 60.00% of users gave Lyra Therapeutics an outperform vote. CompanyUnderperformOutperformLyra TherapeuticsOutperform Votes2460.00% Underperform Votes1640.00% iCADOutperform Votes22862.13% Underperform Votes13937.87% SummaryiCAD beats Lyra Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYRA vs. The Competition Export to ExcelMetricLyra TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.78M$4.33B$5.01B$9.08BDividend YieldN/A41.45%4.87%4.18%P/E Ratio-0.1225.38135.4317.18Price / Sales8.0145.671,119.53115.67Price / CashN/A43.4640.5837.88Price / Book0.127.364.754.78Net Income-$62.68M$13.64M$118.50M$225.60M7 Day Performance-1.42%-2.76%-1.83%-1.26%1 Month Performance1.12%0.38%12.27%4.37%1 Year Performance-95.96%44.25%31.72%18.73% Lyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYRALyra Therapeutics2.411 of 5 stars$0.18+5.9%$4.50+2,400.0%-96.0%$11.78M$1.47M-0.1250Gap DownICADiCAD0.2943 of 5 stars$1.84-5.6%N/A+10.9%$48.83M$18.94M-15.0067NTRBNutriband0.4069 of 5 stars$4.39+6.0%N/A+63.2%$48.76M$2.02M-5.8310Positive NewsGap UpLUCDLucid Diagnostics2.139 of 5 stars$0.81+2.5%$3.63+350.3%-43.0%$47.77M$4.19M-0.6970News CoverageHigh Trading VolumeBLACBellevue Life Sciences AcquisitionN/A$11.26-0.5%N/A+7.6%$45.49MN/A0.00N/ACLGNCollPlant Biotechnologies2.7297 of 5 stars$3.67-0.5%$12.50+240.6%-35.3%$42.02M$10.96M-2.3870Positive NewsCOCHEnvoy Medical3.2024 of 5 stars$1.88-4.1%$8.00+325.5%-26.7%$38.07M$320,000.000.0034News CoverageMDAISpectral AI1.9664 of 5 stars$1.97+9.4%$4.50+128.4%-32.5%$36.62M$18.06M-3.1178SURGSurgePays2.4882 of 5 stars$1.73-2.8%$8.50+391.3%-67.6%$34.88M$137.14M-1.5822XAIRBeyond Air4.1385 of 5 stars$0.48+3.2%$3.67+663.9%-78.9%$34.65M$1.16M-0.3370NXGLNEXGEL0.6527 of 5 stars$4.98+5.7%N/A+125.2%$33.82M$6.73M-8.1210High Trading Volume Related Companies and Tools Related Companies ICAD Competitors NTRB Competitors LUCD Competitors BLAC Competitors CLGN Competitors COCH Competitors MDAI Competitors SURG Competitors XAIR Competitors NXGL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LYRA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
